Cervical Cancer Vaccine Shows 100% Prevention
I wrote about the sexually transmitted Human Papillomovirus (HPV) on the very first day I ever blogged. I titled it 'Let Us Pray', 'Just Say No to Cancer', because wouldn't you think the news of a vaccine that would cure something that is known to be responsible for 70% of the current cases of cervical cancer in women would be greeted with jubliance and delight from everyone? Well yes, you would think so but, Bridget Maher of the conservative Family Research Council said her group would oppose such a vaccine and "the best way to prevent HPV is through abstinence".
You know, I believe in religious freedom but when someone's religious beliefs stand in the way of science, medicine, common sense and me, they've taken it too far. If you want to go around believing Noah had dinosaurs on his big boat, fine, go for it. But when it comes to science, medicine and me, shut the fuck up and stay out of my business!
Monday, 10 October 2005, 9:35 am
Press Release: CSL Limited
Media Release
Investigational Vaccine Prevented 100% High Grade Cervical Pre-Cancers, And Non-Invasive Cervical Cancers (*) in Phase III Study
MELBOURNE Oct. 7 2005 – CSL Limited announced today that GARDASIL™ (Quadrivalent Human Papillomavirus Types 16, 18 6, 11 Recombinant Vaccine), an investigational vaccine developed by Merck & Co., Inc., based on technology licensed from CSL, prevented 100 percent of high-grade cervical pre-cancers and non-invasive cervical cancers (CIN 2/3 and AIS) associated with human papillomavirus (HPV) types 16 and 18 which account for 70 percent of all cervical cancers (*).
The Company advised that the trial compared GARDASIL to placebo in women who were not infected with HPV 16 and 18 at enrolment and who remained free of infection through the completion of the vaccination regimen.
A secondary analysis of the trial data demonstrated that even trial women who may have become infected with HPV16 or 18 during the trial period or who violated the protocol in significant ways were at a reduced risk of developing high grade pre-cancer and non-invasive cervical cancer.
The Company noted that Merck remained on track to submit a Biologics Licence Application for GARDASIL™ to the Food and Drug Administration (FDA) in the fourth quarter of 2005, with a regulatory file being submitted to the Therapeutic Goods Administration (TGA) in Australia and Medsafe in New Zealand, soon thereafter.
‘These results could not be better’, Dr Brian McNamee Managing Director of CSL Limited said today.
Monday, October 10, 2005
A CURE FOR CANCER!
Cervical Cancer Vaccine Shows 100% Prevention
I wrote about the sexually transmitted Human Papillomovirus (HPV) on the very first day I ever blogged. I titled it 'Let Us Pray', 'Just Say No to Cancer', because wouldn't you think the news of a vaccine that would cure something that is known to be responsible for 70% of the current cases of cervical cancer in women would be greeted with jubliance and delight from everyone? Well yes, you would think so but, Bridget Maher of the conservative Family Research Council said her group would oppose such a vaccine and "the best way to prevent HPV is through abstinence".
You know, I believe in religious freedom but when someone's religious beliefs stand in the way of science, medicine, common sense and me, they've taken it too far. If you want to go around believing Noah had dinosaurs on his big boat, fine, go for it. But when it comes to science, medicine and me, shut the fuck up and stay out of my business!
Monday, 10 October 2005, 9:35 am
Press Release: CSL Limited
Media Release
Investigational Vaccine Prevented 100% High Grade Cervical Pre-Cancers, And Non-Invasive Cervical Cancers (*) in Phase III Study
MELBOURNE Oct. 7 2005 – CSL Limited announced today that GARDASIL™ (Quadrivalent Human Papillomavirus Types 16, 18 6, 11 Recombinant Vaccine), an investigational vaccine developed by Merck & Co., Inc., based on technology licensed from CSL, prevented 100 percent of high-grade cervical pre-cancers and non-invasive cervical cancers (CIN 2/3 and AIS) associated with human papillomavirus (HPV) types 16 and 18 which account for 70 percent of all cervical cancers (*).
The Company advised that the trial compared GARDASIL to placebo in women who were not infected with HPV 16 and 18 at enrolment and who remained free of infection through the completion of the vaccination regimen.
A secondary analysis of the trial data demonstrated that even trial women who may have become infected with HPV16 or 18 during the trial period or who violated the protocol in significant ways were at a reduced risk of developing high grade pre-cancer and non-invasive cervical cancer.
The Company noted that Merck remained on track to submit a Biologics Licence Application for GARDASIL™ to the Food and Drug Administration (FDA) in the fourth quarter of 2005, with a regulatory file being submitted to the Therapeutic Goods Administration (TGA) in Australia and Medsafe in New Zealand, soon thereafter.
‘These results could not be better’, Dr Brian McNamee Managing Director of CSL Limited said today.
WANTED
Dead or Alive
